Personalis Inc Stock Research

Market Summary

USD2.60-0.11

Market Closed

-4.06%

PSNL Stock Price

PSNL RSI Chart

PSNL Valuation

Market Cap

121.4M

Price/Earnings (Trailing)

-1.07

Price/Sales (Trailing)

1.87

EV/EBITDA

-0.31

Price/Free Cashflow

-1.01

PSNL Price/Sales (Trailing)

PSNL Profitability

Operating Margin

20.52%

EBT Margin

-174.14%

Return on Equity

-51.95%

Return on Assets

-38.71%

Free Cashflow Yield

-98.92%

PSNL Fundamentals

PSNL Revenue

Revenue (TTM)

65.0M

Revenue Y/Y

-19.15%

Revenue Q/Q

12.55%

PSNL Earnings

Earnings (TTM)

-113.3M

Earnings Y/Y

-53.81%

Earnings Q/Q

-17.27%

Price Action

52 Week Range

1.738.96

(Low)(High)

Last 7 days

-10.3%

Last 30 days

-18.2%

Last 90 days

33.3%

Trailing 12 Months

-68.4%

PSNL Financial Health

Current Ratio

6.03

PSNL Investor Care

Shares Dilution (1Y)

4.01%

Diluted EPS (TTM)

-2.48

Peers (Alternatives to Personalis)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
A	38.9B	6.8B	-7.12%	-2.94%	31.04	5.68	8.37%	3.64%
IQV	35.0B	14.4B	-10.73%	-16.15%	32.06	2.43	3.86%	12.94%
ILMN	34.8B	4.6B	9.07%	-35.87%	-7.89	7.58	1.28%	-677.95%
CRL	9.9B	4.0B	-11.55%	-31.05%	20.3	2.48	12.31%	24.36%
MID-CAP
MEDP	5.7B	1.5B	-7.14%	13.35%	23.05	3.87	27.80%	34.93%
SYNH	3.6B	5.4B	-7.30%	-56.29%	13.33	0.66	3.46%	13.48%
SMALL-CAP
PACB	2.2B	128.3M	3.11%	-0.62%	-6.93	16.97	-1.69%	-73.40%
ADPT	1.2B	185.3M	-4.53%	-36.18%	-6.03	6.51	20.06%	3.42%
CSTL	597.7M	137.0M	-4.54%	-49.04%	-8.9	4.36	45.65%	-114.55%
NVTA	316.8M	516.3M	-37.38%	-84.33%	-0.1	0.61	12.13%	-719.59%
CDXS	255.3M	138.6M	-29.45%	-81.04%	-7.6	1.84	32.30%	-57.86%
PSNL	121.4M	65.0M	-18.24%	-68.45%	-1.07	1.87	-23.92%	-73.73%

Financials for Personalis

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-5.7%	65,047,000	69,007,000	76,410,000	79,840,000	85,494,000
S&GA Expenses	6.9%	63,969,000	59,850,000	57,209,000	52,763,000	47,698,000
R&D Expenses	3.3%	64,912,000	62,855,000	61,515,000	56,914,000	49,312,000
EBITDA	-10.0%	-104,642,000	-95,129,000	-86,666,000	-74,450,000	-
EBITDA Margin	-16.7%	-1.61	-1.38	-1.13	-0.93	-
Earnings Before Taxes	-10.6%	-113,275,000	-102,417,000	-93,594,000	-81,007,000	-65,212,000
EBT Margin	-17.3%	-1.74	-1.48	-1.22	-1.01	-
Interest Expenses	-5.6%	201,000	213,000	228,000	243,000	184,000
Net Income	-10.6%	-113,315,000	-102,446,000	-93,624,000	-81,031,000	-65,226,000
Net Income Margin	-17.3%	-1.74	-1.48	-1.23	-1.01	-
Free Cahsflow	-6.6%	-120,129,000	-112,680,000	-97,343,000	-89,720,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-7.9%	293	318	358	381	397
Current Assets	-10.0%	200	222	260	294	318
Cash Equivalents	6.7%	89.00	84.00	87.00	92.00	106
Net PPE	1.2%	62.00	61.00	48.00	31.00	20.00
Liabilities	-1.2%	75.00	75.00	93.00	94.00	86.00
Current Liabilities	-1.8%	33.00	34.00	42.00	40.00	31.00
Shareholder's Equity	-10.0%	218	242	265	287	310
Retained Earnings	-9.4%	-360	-329	-302	-275	-247
Additional Paid-In Capital	1.1%	579	573	569	563	558
Accumulated Depreciation	7.5%	24.00	23.00	21.00	19.00	-
Shares Outstanding	1.6%	47.00	46.00	46.00	45.00	45.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-2.2%	-70.23	-68.74	-71.86	-70.44	-70.83
Share Based Compensation	9.9%	19.00	18.00	17.00	16.00	14.00
Cashflow From Investing	-25.6%	53.00	71.00	89.00	19.00	-60.07
Cashflow From Financing	-38.0%	1.00	2.00	1.00	7.00	170

Risks for PSNL

What is the probability of a big loss on PSNL?

99.0%

Probability that Personalis stock will be more than 20% underwater in next one year

97.5%

Probability that Personalis stock will be more than 30% underwater in next one year.

96.0%

Probability that Personalis stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PSNL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Personalis was unfortunately bought at previous high price.

Drawdowns

Returns for PSNL

Cumulative Returns on PSNL

-26.4%

3-Year Cumulative Returns

Which funds bought or sold PSNL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-02-15	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	reduced	-33.6	-42,000	34,000	-%
2023-02-15	Bruce & Co., Inc.	new	-	99,000	99,000	0.03%
2023-02-15	Wellington Shields Capital Management, LLC	reduced	-11.51	-1,187,990	1,709,010	0.21%
2023-02-15	Wellington Shields & Co., LLC	added	9.39	-744,640	2,006,360	0.46%
2023-02-15	JANE STREET GROUP, LLC	reduced	-20.38	-43,397	49,603	-%
2023-02-15	Steward Partners Investment Advisory, LLC	unchanged	-	198	198	-%
2023-02-15	Financial Gravity Asset Management, Inc.	new	-	8.00	8.00	-%
2023-02-15	B. Riley Asset Management, LLC	new	-	248,827	248,827	0.11%
2023-02-14	Point72 Hong Kong Ltd	sold off	-100	-	-	-%
2023-02-14	LMR Partners LLP	sold off	-100	-51,000	-	-%

Latest Funds Activity

Are funds buying PSNL calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own PSNL

No. of Funds

Personalis News

Schedule 13G FIlings of Personalis

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 31, 2023	blackrock inc.	7.7%	3,558,913	SC 13G/A
Jan 25, 2023	jpmorgan chase & co	7.6%	3,502,353	SC 13G/A
Mar 09, 2022	blackrock inc.	10.0%	4,502,224	SC 13G/A
Mar 07, 2022	lightspeed venture partners viii lp	9.16%	4,117,768	SC 13D/A
Feb 09, 2022	ark investment management llc	10.91%	4,888,115	SC 13G/A
Feb 03, 2022	blackrock inc.	9.8%	4,389,333	SC 13G/A
Jan 14, 2022	jpmorgan chase & co	9.5%	4,267,659	SC 13G/A
Feb 16, 2021	abingworth llp	0.0%	0	SC 13G/A
Feb 02, 2021	blackrock inc.	5.9%	2,309,401	SC 13G
Jan 15, 2021	jpmorgan chase & co	8.5%	3,340,089	SC 13G

PSNL Fair Value

Personalis fair value in different scenarios

The table shows the Fair Value estimates for Personalis for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	1.19 -54.23%	1.26 -51.54%	1.39 -46.54%	1.65 -36.54%	1.90 -26.92%
Current Inflation	1.19 -54.23%	1.25 -51.92%	1.37 -47.31%	1.60 -38.46%	1.82 -30.00%
Very High Inflation	1.19 -54.23%	1.24 -52.31%	1.35 -48.08%	1.54 -40.77%	1.73 -33.46%

Historical Personalis Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Personalis

View All Filings

Date Filed	Form Type	Document
Mar 21, 2023	4	Insider Trading
Mar 21, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 08, 2023	8-K	Current Report
Feb 23, 2023	10-K	Annual Report
Feb 23, 2023	8-K	Current Report
Feb 23, 2023	S-8	Employee Benefits Plan

Latest Insider Trading transactions for PSNL

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-17	Tachibana Aaron	sold	-11,164	2.83	-3,945	cfo and coo
2023-03-17	Chen Richard	sold	-3,718	2.83	-1,314	chief medical officer and evp
2023-01-31	Chen Richard	sold	-1,236	2.2	-562	chief medical officer
2023-01-31	Tachibana Aaron	sold	-1,687	2.2	-767	chief financial officer
2022-12-20	Chen Richard	sold	-3,360	1.92	-1,750	chief medical officer
2022-12-20	Tachibana Aaron	sold	-7,378	1.92	-3,843	chief financial officer
2022-12-15	Chen Richard	sold	-17,942	2.5	-7,177	chief medical officer
2022-12-15	Tachibana Aaron	sold	-17,942	2.5	-7,177	chief financial officer
2022-12-15	Moore Stephen Michael	sold	-4,825	2.5	-1,930	general counsel
2022-12-14	West John Stephen	acquired	24,400	2.44	10,000	president and ceo

About Personalis

John S. West

www.personalis.com

330

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

PSNL Income Statement

2022-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 65,047	$ 85,494	$ 78,648
Costs and expenses
Cost of revenue	51,697	53,837	58,534
Research and development	64,912	49,312	28,568
Selling, general and administrative	63,969	47,698	33,692
Total costs and expenses	180,578	150,847	120,794
Loss from operations	(115,531)	(65,353)	(42,146)
Interest income	2,396	367	949
Interest expense	(201)	(184)	(2)
Other income (expense), net	61	(42)	(24)
Loss before income taxes	(113,275)	(65,212)	(41,223)
Provision for income taxes	40	14	57
Net loss	$ (113,315)	$ (65,226)	$ (41,280)
Net loss per share, basic	$ (2.48)	$ (1.49)	$ (1.20)
Net loss per share, diluted	$ (2.48)	$ (1.49)	$ (1.20)
Weighted-average shares outstanding, basic	45,704,805	43,886,730	34,374,903
Weighted-average shares outstanding, diluted	45,704,805	43,886,730	34,374,903

PSNL Balance Sheet

2022-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 89,128	$ 105,585
Short-term investments	78,530	181,479
Accounts receivable, net	16,642	18,468
Inventory and other deferred costs	8,591	5,610
Prepaid expenses and other current assets	6,808	7,089
Total current assets	199,699	318,231
Property and equipment, net	61,935	19,650
Operating lease right-of-use assets	26,480	53,822
Other long-term assets	4,586	4,825
Total assets	292,700	396,528
Current liabilities
Accounts payable	12,854	9,221
Accrued and other current liabilities	19,013	18,110
Contract liabilities	1,264	3,982
Total current liabilities	33,131	31,313
Long-term operating lease liabilities	41,041	52,797
Other long-term liabilities	389	2,117
Total liabilities	74,561	86,227
Commitments and contingencies (Note 12)
Stockholders’ equity
Common stock, $0.0001 par value - 200,000,000 shares authorized; 46,707,084 and 44,904,512 shares issued and outstanding at December 31, 2022 and 2021, respectively	5	4
Additional paid-in capital	579,456	557,558
Accumulated other comprehensive loss	(912)	(166)
Accumulated deficit	(360,410)	(247,095)
Total stockholders’ equity	218,139	310,301
Total liabilities and stockholders’ equity	$ 292,700	$ 396,528